Dr. Heather Shannon Ogando, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 135 Park Blvd, Box 308, Massapequa Park, NY 11762 Phone: 516-795-9090 |
Alessandra Bruzzese, MSN RN, AGPCNP-C Family Medicine - Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 127 Whitewood Dr, Massapequa Park, NY 11762 Phone: 516-965-8421 |
Janet Widerspan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 50 Larch Ln, Massapequa Park, NY 11762 Phone: 516-804-4899 |
Robert Andrew Tufano, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Park Blvd, Rear Annex, Massapequa Park, NY 11762 Phone: 516-795-8446 |
News Archive
Vitals is pleased to announce that Dr. Jason Wendel has been honored with the prestigious 2013 Compassionate Doctor Award.
Underage drinking is a concern all over the country. Among American Indian and Alaska Native populations, there are especially serious issues: alcohol use and heavy drinking at an early age increase risks for lifetime alcohol problems, and American Indians and Native Alaskans have reported younger onsets than other groups.
Children who are given high-quality education at an early age - starting at six weeks old and continuing through their first five years of life - are more likely to be employed full-time and have better relationships with their parents as adults, according to new results from a longitudinal study now entering its fifth decade.
The world's only online image-based COVID-19 diagnosis improvement tool for healthcare workers is launched today by University of Sydney spinoff DetectED-X, drawing on its global experience and outcomes in breast cancer detection and patient cases from the coronavirus pandemic.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRAâ„¢ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
› Verified 6 days ago